Use access key #2 to skip to page content.
$69.08 -0.55 (-0.79%)
5/16/2008 4:00 PM

Genzyme Corp (GENZ)

CAPS Rating:
*****

A biotechnology company dedicated to making an impact on the lives of people with serious diseases. Its product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, and diagnostic and predictive testing.

View All Commentary (GENZ)

Recs

0

Avatar Budsworth (94.41) Submitted: 4/05/08 5:29 AM : Outperform Start Price: $75.95 GENZ Score: -12.49

With the most recent resolution over manufacturing issues of MYOZYME enzyme replacement therapy for Pomp disease: should help gain favor with the FDA.
They will be announcing mid stage data for the drug CLOLAR at the American Society for Clinical Oncology Conference. It is a treatment for childhood leukemia. They feel they have some very positive news to reveal. Also they will be announcing data for a treatment for oral Gaucher disease to be released in mid 2008.
They are very excited about this most recent positive news.
A well managed Bio-company with some real positive news. I'll go with them on this!

Report this Post Replies: 0 | Reply

Featured Broker Partners